Enanta Pharmaceuticals Inc. (ENTA)

Business: Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases.

IPO Date: 21-Mar-2013

Pres, CEO & Director: Dr. Jay R. Luly

Sr. VP of Fin. & Admin. and CFO: Mr. Paul J. Mellett Jr.

Listing: NASDAQ: ENTA

Country: United States

Headquarters: Watertown, MA

Website: https://www.enanta.com

Market cap: $922.75 Mln

Revenue (TTM): $91.56 Mln

Earnings (TTM): $-112.33 Mln

Cash: $280.33 Mln

Total Debt: $18.13 Mln

Insider's Holding: 6.09%

Liquidity: Low

52 Week range: $37.59 - 102.00

Shares outstanding: 20,712,700

10 Years Aggregate:

• CFO: $256.32 Mln
• EBITDA: $257.17 Mln
• Net Profit: $187.01 Mln